Studies of a controlled-release microcapsule formulation of an LH-RH agonist (D-Trp-6-LH-RH) in the rhesus monkey menstrual cycle

R. H. Asch, F. J. Rojas, T. R. Tice, Andrew V Schally

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

It has been shown that continuous administration of LH-RH agonists inhibits ovulation in many species, including human and nonhuman primates. However, the need of daily injections or intranasal application of the LH-RH agonists makes this contraceptive approach impractical. In addition, due to the repeated daily administration of the LH-RH analogues and their bioavailability, serum levels of gonadotropins and estradiol present wide variations and are often associated with irregular bleeding and/or endometrial hyperplasia. This experiment was designed to study the effects on ovulation and the hormonal profile during the rhesus monkey menstrual cycle of a system that continuously delivers a potent agonist of LH-RH (D-Trp-6-LH-RH encapsulated in poly [DL-lactide-co-glycolide]). Subjects were divided into two groups: On day 1 of the cycle, monkeys received a single subcutaneous injection of microcapsules containing D-Trp-6-LH-RH at a release rate of 13.6 μg/day (Group 1) or placebo microcapsules (Group 2). Ovulation dates were significantly delayed in animals from Group 1 (50 ± 3 days) as compared to those in group 2 (20 ±2 days). Luteal phases following ovulation were normal in animals of both groups, as determined by length and serum progesterone levels. No significant differences on baseline levels of FSH and LH were observed between the two groups of animals. Post-treatment cycles were ovulatory and presented normal luteal phases and hormone concentrations as compared to the non-treated animals of our colony. The present data show for the first time that a controlled-release formulation that delivers an agonist of LH-RH can effectively suppress ovulation when injected in a single dose in non-human primates.

Original languageEnglish
Pages (from-to)19-26
Number of pages8
JournalInternational Journal of Fertility
Volume30
Issue number2
StatePublished - Jan 1 1985
Externally publishedYes

Fingerprint

Triptorelin Pamoate
Menstrual Cycle
Ovulation
Macaca mulatta
Gonadotropin-Releasing Hormone
Capsules
Luteal Phase
Primates
Corpus Luteum Hormones
Endometrial Hyperplasia
Polyglactin 910
Subcutaneous Injections
Contraceptive Agents
Serum
Gonadotropins
Biological Availability
Haplorhini
Progesterone
Estradiol
Placebos

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Studies of a controlled-release microcapsule formulation of an LH-RH agonist (D-Trp-6-LH-RH) in the rhesus monkey menstrual cycle. / Asch, R. H.; Rojas, F. J.; Tice, T. R.; Schally, Andrew V.

In: International Journal of Fertility, Vol. 30, No. 2, 01.01.1985, p. 19-26.

Research output: Contribution to journalArticle

@article{6b7bc64ebf4040d4823d4c0f6b452670,
title = "Studies of a controlled-release microcapsule formulation of an LH-RH agonist (D-Trp-6-LH-RH) in the rhesus monkey menstrual cycle",
abstract = "It has been shown that continuous administration of LH-RH agonists inhibits ovulation in many species, including human and nonhuman primates. However, the need of daily injections or intranasal application of the LH-RH agonists makes this contraceptive approach impractical. In addition, due to the repeated daily administration of the LH-RH analogues and their bioavailability, serum levels of gonadotropins and estradiol present wide variations and are often associated with irregular bleeding and/or endometrial hyperplasia. This experiment was designed to study the effects on ovulation and the hormonal profile during the rhesus monkey menstrual cycle of a system that continuously delivers a potent agonist of LH-RH (D-Trp-6-LH-RH encapsulated in poly [DL-lactide-co-glycolide]). Subjects were divided into two groups: On day 1 of the cycle, monkeys received a single subcutaneous injection of microcapsules containing D-Trp-6-LH-RH at a release rate of 13.6 μg/day (Group 1) or placebo microcapsules (Group 2). Ovulation dates were significantly delayed in animals from Group 1 (50 ± 3 days) as compared to those in group 2 (20 ±2 days). Luteal phases following ovulation were normal in animals of both groups, as determined by length and serum progesterone levels. No significant differences on baseline levels of FSH and LH were observed between the two groups of animals. Post-treatment cycles were ovulatory and presented normal luteal phases and hormone concentrations as compared to the non-treated animals of our colony. The present data show for the first time that a controlled-release formulation that delivers an agonist of LH-RH can effectively suppress ovulation when injected in a single dose in non-human primates.",
author = "Asch, {R. H.} and Rojas, {F. J.} and Tice, {T. R.} and Schally, {Andrew V}",
year = "1985",
month = "1",
day = "1",
language = "English",
volume = "30",
pages = "19--26",
journal = "International Journal of Fertility",
issn = "0020-725X",
publisher = "MSP International",
number = "2",

}

TY - JOUR

T1 - Studies of a controlled-release microcapsule formulation of an LH-RH agonist (D-Trp-6-LH-RH) in the rhesus monkey menstrual cycle

AU - Asch, R. H.

AU - Rojas, F. J.

AU - Tice, T. R.

AU - Schally, Andrew V

PY - 1985/1/1

Y1 - 1985/1/1

N2 - It has been shown that continuous administration of LH-RH agonists inhibits ovulation in many species, including human and nonhuman primates. However, the need of daily injections or intranasal application of the LH-RH agonists makes this contraceptive approach impractical. In addition, due to the repeated daily administration of the LH-RH analogues and their bioavailability, serum levels of gonadotropins and estradiol present wide variations and are often associated with irregular bleeding and/or endometrial hyperplasia. This experiment was designed to study the effects on ovulation and the hormonal profile during the rhesus monkey menstrual cycle of a system that continuously delivers a potent agonist of LH-RH (D-Trp-6-LH-RH encapsulated in poly [DL-lactide-co-glycolide]). Subjects were divided into two groups: On day 1 of the cycle, monkeys received a single subcutaneous injection of microcapsules containing D-Trp-6-LH-RH at a release rate of 13.6 μg/day (Group 1) or placebo microcapsules (Group 2). Ovulation dates were significantly delayed in animals from Group 1 (50 ± 3 days) as compared to those in group 2 (20 ±2 days). Luteal phases following ovulation were normal in animals of both groups, as determined by length and serum progesterone levels. No significant differences on baseline levels of FSH and LH were observed between the two groups of animals. Post-treatment cycles were ovulatory and presented normal luteal phases and hormone concentrations as compared to the non-treated animals of our colony. The present data show for the first time that a controlled-release formulation that delivers an agonist of LH-RH can effectively suppress ovulation when injected in a single dose in non-human primates.

AB - It has been shown that continuous administration of LH-RH agonists inhibits ovulation in many species, including human and nonhuman primates. However, the need of daily injections or intranasal application of the LH-RH agonists makes this contraceptive approach impractical. In addition, due to the repeated daily administration of the LH-RH analogues and their bioavailability, serum levels of gonadotropins and estradiol present wide variations and are often associated with irregular bleeding and/or endometrial hyperplasia. This experiment was designed to study the effects on ovulation and the hormonal profile during the rhesus monkey menstrual cycle of a system that continuously delivers a potent agonist of LH-RH (D-Trp-6-LH-RH encapsulated in poly [DL-lactide-co-glycolide]). Subjects were divided into two groups: On day 1 of the cycle, monkeys received a single subcutaneous injection of microcapsules containing D-Trp-6-LH-RH at a release rate of 13.6 μg/day (Group 1) or placebo microcapsules (Group 2). Ovulation dates were significantly delayed in animals from Group 1 (50 ± 3 days) as compared to those in group 2 (20 ±2 days). Luteal phases following ovulation were normal in animals of both groups, as determined by length and serum progesterone levels. No significant differences on baseline levels of FSH and LH were observed between the two groups of animals. Post-treatment cycles were ovulatory and presented normal luteal phases and hormone concentrations as compared to the non-treated animals of our colony. The present data show for the first time that a controlled-release formulation that delivers an agonist of LH-RH can effectively suppress ovulation when injected in a single dose in non-human primates.

UR - http://www.scopus.com/inward/record.url?scp=0021929895&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021929895&partnerID=8YFLogxK

M3 - Article

VL - 30

SP - 19

EP - 26

JO - International Journal of Fertility

JF - International Journal of Fertility

SN - 0020-725X

IS - 2

ER -